Ernexa Therapeutics Inc. ERNA

CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1 Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors Access the Ernexa CEO Corner here CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing nov

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy Biodistribution study showed no significant ERNA-101 signal in tumor-free

Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on October 6, 2026, at 1:30 PM Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101 in platinum-resistant ovarian cancer and its potential for broader expansion across ovarian cancer and other solid tumor indications Differentiated synthetic iMSC platform design

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the

ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology Positive ERNA-201 findings add to a growing body of preclinical evidence supporting the versatility of Ernexa's synthetic iMSC platform and its ability to deliver engineered therapeutic factors in disease Company is concentrating near-term resources on ERNA-101 while broadening

President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment

Video webcast now available here CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, presented the Company’s investment thesis and highlighted why he believes

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026 Access the Ernexa CEO Corner here CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutic

Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical data supporting its lead cell therapy candidate, ERNA-101, for the treatment of ovarian cancer. Independent research confirms earlier findingsThe company said an independent contract research organisation successfully replicated previous results, demonstrating complete tumour clearance and extended survival in a larger preclinical study.

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Survival in Two-Thirds of Treated Animals While No Complete Responses Were Observed in Any Monotherapy or Control Group IND Submission Planned for Q3 2026 with First-in-Human Phase 1 Trial Expected to Begin in Q4 2026 CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWI

CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward planned first-in-human clinical evaluation IND submission planned for the third quarter of 2026 with first-in-human Phase 1 study anticipated to begin in the fourth quarter of 2026 Access the Ernexa CEO Corner here CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWI

New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability Inaugural video highlights Company's mission to provide hope, scientific strategy and commitment to advancing differentiated cell therapies Access the Ernexa CEO Corner here CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapie

Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant progress across manufacturing, regulatory and clinical development